Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.

Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.

J Clin Pharmacol. 2019 Jul 19. doi: 10.1002/jcph.1480. [Epub ahead of print]

PMID:
31322739
2.

In Vitro Drug-Drug Interaction Evaluation of GalNAc conjugated siRNAs Against CYP450 Enzymes and Transporters.

Ramsden D, Wu JT, Zerler B, Iqbal S, Jiang J, Clausen V, Aluri K, Gu Y, Dennin S, Kim J, Chong S.

Drug Metab Dispos. 2019 Jul 3. pii: dmd.119.087098. doi: 10.1124/dmd.119.087098. [Epub ahead of print]

3.

Cosilencing Intestinal Transglutaminase-2 and Interleukin-15 Using Gelatin-Based Nanoparticles in an in Vitro Model of Celiac Disease.

Attarwala H, Clausen V, Chaturvedi P, Amiji MM.

Mol Pharm. 2017 Sep 5;14(9):3036-3044. doi: 10.1021/acs.molpharmaceut.7b00233. Epub 2017 Aug 10.

PMID:
28737923
4.

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A.

N Engl J Med. 2017 Jan 5;376(1):41-51. doi: 10.1056/NEJMoa1609243. Epub 2016 Nov 13.

5.

Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.

Zhang N, Zhang X, Zhu J, Turpoff A, Chen G, Morrill C, Huang S, Lennox W, Kakarla R, Liu R, Li C, Ren H, Almstead N, Venkatraman S, Njoroge FG, Gu Z, Clausen V, Graci J, Jung SP, Zheng Y, Colacino JM, Lahser F, Sheedy J, Mollin A, Weetall M, Nomeir A, Karp GM.

J Med Chem. 2014 Mar 13;57(5):2121-35. doi: 10.1021/jm401621g. Epub 2013 Dec 4.

PMID:
24266880
6.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A.

Lancet. 2014 Jan 4;383(9911):60-68. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3.

7.

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB.

N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760.

8.

Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.

Zhang X, Zhang N, Chen G, Turpoff A, Ren H, Takasugi J, Morrill C, Zhu J, Li C, Lennox W, Paget S, Liu Y, Almstead N, Njoroge FG, Gu Z, Komatsu T, Clausen V, Espiritu C, Graci J, Colacino J, Lahser F, Risher N, Weetall M, Nomeir A, Karp GM.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3947-53. doi: 10.1016/j.bmcl.2013.04.049. Epub 2013 Apr 30.

PMID:
23683597
9.

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd.

Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28.

10.

Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles.

Nakayama T, Butler JS, Sehgal A, Severgnini M, Racie T, Sharman J, Ding F, Morskaya SS, Brodsky J, Tchangov L, Kosovrasti V, Meys M, Nechev L, Wang G, Peng CG, Fang Y, Maier M, Rajeev KG, Li R, Hettinger J, Barros S, Clausen V, Zhang X, Wang Q, Hutabarat R, Dokholyan NV, Wolfrum C, Manoharan M, Kotelianski V, Stoffel M, Sah DW.

Mol Ther. 2012 Aug;20(8):1582-9. doi: 10.1038/mt.2012.33. Epub 2012 Jun 5.

11.

Biochemical characterization of the first essential two-component signal transduction system from Staphylococcus aureus and Streptococcus pneumoniae.

Clausen VA, Bae W, Throup J, Burnham MK, Rosenberg M, Wallis NG.

J Mol Microbiol Biotechnol. 2003;5(4):252-60.

PMID:
12867749
12.
13.

Cyanohydrin glycosides of Passiflora: distribution pattern, a saturated cyclopentane derivative from P. guatemalensis, and formation of pseudocyanogenic alpha-hydroxyamides as isolation artefacts.

Jaroszewski JW, Olafsdottir ES, Wellendorph P, Christensen J, Franzyk H, Somanadhan B, Budnik BA, Jørgensen LB, Clausen V.

Phytochemistry. 2002 Mar;59(5):501-11.

PMID:
11853745
14.

Cyclopentanoids of Mathurina penduliflora.

Wellendorph P, Clausen V, Jørgensen LB, Jaroszewski JW.

Biochem Syst Ecol. 2001 Jun;29(6):649-651. No abstract available.

PMID:
11336813
15.

Stereochemical analysis of the reaction catalyzed by human protein geranylgeranyl transferase.

Clausen VA, Edelstein RL, Distefano MD.

Biochemistry. 2001 Apr 3;40(13):3920-30.

PMID:
11300771
16.

Tetraphyllin B, volkenin and cyclopentenylglycine in Androsiphonia adenostegia.

Clausen V V, Wellendorph P, Ekpe P, Jaroszewski JW.

Biochem Syst Ecol. 2001 Mar;29(3):317-319. No abstract available.

PMID:
11152950
17.

Gynocardin and cyclopentenylglycine in Rawsonia lucida.

Andersen L, Clausen V V, Oketch-Rabah HA, Lechtenberg M, Adsersen A, Nahrstedt A, Jaroszewski JW.

Biochem Syst Ecol. 2001 Feb 1;29(2):219-222. No abstract available.

PMID:
11106854
18.

NMR investigations of duplex stability of phosphorothioate and phosphorodithioate DNA analogues modified in both strands.

Jaroszewski JW, Clausen V, Cohen JS, Dahl O.

Nucleic Acids Res. 1996 Mar 1;24(5):829-34.

19.

[Goiter incidence in Germany is greater than previously suspected].

Hampel R, Külberg T, Klein K, Jerichow JU, Pichmann EG, Clausen V, Schmidt I.

Med Klin (Munich). 1995 Jun 15;90(6):324-9. German.

PMID:
7637663
20.

Patient education programmes in obstructive airway disease. The Ingelheim Model for promoting health through patient education.

Klein K, Troglauer KG, Ahlstich G, Schunke B, Theissen E, Voss HW, Clausen V.

Allerg Immunol (Paris). 1992 Jun;24(6):216-23.

PMID:
1497798
21.

Novel cyclopentenoid cyanohydrin rhamnoglucosides from flacourtiaceae1.

Jaroszewski JW, Bruun D, Clausen V, Cornett C.

Planta Med. 1988 Aug;54(4):333-7.

PMID:
17265279
22.

16S ribosomal RNA analysis of Filibacter limicola indicates a close relationship to the genus Bacillus.

Clausen V, Jones JG, Stackebrandt E.

J Gen Microbiol. 1985 Oct;131(10):2659-63.

PMID:
2415672
23.

Mekong schistosomiasis in Kampuchean refugees.

Clausen VE, Wagner ED.

Southeast Asian J Trop Med Public Health. 1981 Dec;12(4):603-4. No abstract available.

PMID:
7344111
24.

The influence of small atmospheric ions on human well-being and mental performance.

Albrechtsen O, Clausen V, Christensen FG, Jensen JG, Møller T.

Int J Biometeorol. 1978 Dec;22(4):249-62. No abstract available.

PMID:
750505
25.

THE LIBRARY IN DENTAL RESEARCH.

CLAUSEN VM, GORLIN RJ.

J Dent Educ. 1965 Mar;29:23-34. No abstract available.

PMID:
14260173
26.

The Bio-Medical Library at the University of Minnesota.

CLAUSEN VM.

Bull Med Libr Assoc. 1958 Apr;46(2):270-3. No abstract available.

Supplemental Content

Loading ...
Support Center